OOIR: Observatory of International Research

Papers

(The TQCC of European Respiratory Journal is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study	927
ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19	582
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge	550
Pathogenesis of COVID-19 from a cell biology perspective	545
Cardiovascular comorbidity and its impact on patients with COVID-19	456
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	448
A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis	358
The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19	348
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline	340
ERS/ATS technical standard on interpretive strategies for routine lung function tests	327
Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset	312
Association between age and clinical characteristics and outcomes of COVID-19	280
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial	276
ERS statement on chronic thromboembolic pulmonary hypertension	276
No association of COVID-19 transmission with temperature or UV radiation in Chinese cities	272
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study	270
Pulmonary embolism in patients with COVID-19 pneumonia	266
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?	266
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial	254
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients	249
COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force	248
ERS clinical practice guidelines on treatment of sarcoidosis	242
COVID-19 and pneumothorax: a multicentre retrospective case series	219
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes	217
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19	216

COVID-19 and COPD	212
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China	209
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary	199
Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation	198
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases	197
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective	195
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study	186
Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia	183
High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion	182
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19	179
Universal use of face masks for success against COVID-19: evidence and implications for prevention policies	172
Trends in worldwide asthma prevalence	166
Pathogenesis of COVID-19-induced ARDS: implications for an ageing population	159
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome	152
Will children reveal their secret? The coronavirus dilemma	152
The potential impact of COVID-19-related disruption on tuberculosis burden	148
Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study	146
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry	145
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline	142
The impact of COVID-19 on patients with asthma	142
Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication	141
Patient-reported outcome measures after COVID-19: a prospective cohort study	139
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection	137
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma	136
Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China	135
Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors	135
COVID-19 and smoking: is nicotine the hidden link?	133
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update	130
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study	130
Thrombosis and COVID-19 pneumonia: the clot thickens!	129
Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue	122
Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation	122
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers	117
Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life	116
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review	114
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension	114
Methotrexate and rheumatoid arthritis associated interstitial lung disease	113
Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study	110
Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study	109
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure	108
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection	108
Endothelial cells in the pathogenesis of pulmonary arterial hypertension	106
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase	106
Current smoking is not associated with COVID-19	104
Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital	103
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabversusprofessional-collected nasopharyngeal swab	103
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies	102
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years	102
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis	102
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)	101

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry	101
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis	95
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study	93
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences	93
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial	93
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics	92
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis	91
Novel coronavirus infection in newborn babies aged <28 days in China	91
Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up	91
Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator	88
Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS	87
Effect of asthma and asthma medication on the prognosis of patients with COVID-19	86
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients	86
Social stigma in the time of coronavirus disease 2019	86
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study	85
Between inflammation and thrombosis: endothelial cells in COVID-19	84
On tuberculosis and COVID-19 co-infection	83
Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public	83
European Respiratory Society guidelines for the diagnosis of asthma in adults	83
Managing the supportive care needs of those affected by COVID-19	81
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry	80
Early consensus management for non-ICU acute respiratory failure SARS-CoV-2 emergency in Italy: from ward to trenches	80
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis	80
European Respiratory Society statement on long COVID follow-up	80
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health	79
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline	79
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial	79
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure	79
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation	78
Treatment options in type-2 low asthma	78
Potential of regulatory T-cell-based therapies in the management of severe COVID-19	78
COVID-19, tuberculosis and poverty: preventing a perfect storm	78
Epidemic and pandemic viral infections: impact on tuberculosis and the lung	75
Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow	74
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study	74
Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA)	72
European Respiratory Society statement on thoracic ultrasound	71
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena	70
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation	69
Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis	68
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors	68
COVID-19: guidance on palliative care from a European Respiratory Society international task force	67
Targeting transforming growth factor-β receptors in pulmonary hypertension	67
COVID-19 and pulmonary rehabilitation: preparing for phase three	66
Clinical application of an intelligent oropharyngeal swab robot: implication for the COVID-19 pandemic	64
COVID-19 and nicotine as a mediator of ACE-2	64
Asthma remission: what is it and how can it be achieved?	63
Phenotyping long COVID	62
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)	62
Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients	62
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects	62
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	60
The physiological basis of pulmonary arterial hypertension	60
The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital	60
Effect of aerobic exercise training on asthma in adults: a systematic review and meta-analysis	60
The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study	59
Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease	59
Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial	59
“You can leave your mask on”: effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise	59
EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke	59
Interstitial lung disease increases susceptibility to and severity of COVID-19	59
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry	58
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study	57
Tuberculosis and COVID-19 co-infection: description of the global cohort	57
Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis	57
Sleep-related breathing disorders and pulmonary hypertension	56
Asthma and COVID-19 risk: a systematic review and meta-analysis	56
Metabolomic analyses reveal new stage-specific features of COVID-19	56
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme	56
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry	56
Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study	55
Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs	55
Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation	55
Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis	55
Development and validation of a deep learning algorithm detecting 10 common abnormalities on chest radiographs	55
COVID-19 and the nicotinic cholinergic system	54
Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?	53
Risk factors for viral RNA shedding in COVID-19 patients	52
Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia	52
Low-cost, easy-to-build noninvasive pressure support ventilator for under-resourced regions: open source hardware description, performance and feasibility testing	51

Topological data analysis reveals genotype–phenotype relationships in primary ciliary dyskinesia	50
Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection	50
Highly sensitive and specific diagnosis of COVID-19 by reverse transcription multiple cross-displacement amplification-labelled nanoparticles biosensor	50
Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy	50
Vascular permeability in the fibrotic lung	50
Epigenetics and pulmonary diseases in the horizon of precision medicine: a review	49
Comorbid insomnia and sleep apnoea is associated with all-cause mortality	49
High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU	48
Short-acting β₂-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study	48
European Respiratory Society statement on sleep apnoea, sleepiness and driving risk	48
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation	48
A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis	48
Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?	48
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry	48
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk	48
Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection	47
Emergence of bedaquiline resistance in a high tuberculosis burden country	47
Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study	47
Smoking, ACE-2 and COVID-19: ongoing controversies	47
Elevated pulmonary vascular resistance predicts mortality in COPD patients	47
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody	47
COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry	47
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial	46
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	46
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial	46
Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB	46
The perils of premature phenotyping in COVID-19: a call for caution	46
Air pollution and the development of asthma from birth until young adulthood	46
Estimates of the ongoing need for social distancing and control measures post-“lockdown” from trajectories of COVID-19 cases and mortality	46
Artificial intelligence techniques in asthma: a systematic review and critical appraisal of the existing literature	45
SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis	45
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease	45
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma	44
Environmental fungal sensitisation associates with poorer clinical outcomes in COPD	44
Asthma management in low and middle income countries: case for change	44
Short-term outcomes of COVID-19 and risk factors for progression	44
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support	44
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry	44
Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?	43
Go slow to go fast: a plea for sustained scientific rigour in air pollution research during the COVID-19 pandemic	43
When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases	43
Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)	43
Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort	42
Lung function trajectory in progressive fibrosing interstitial lung disease	42
Steroid use in elderly critically ill COVID-19 patients	42
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis	41
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial	41
World Health Organization treatment outcome definitions for tuberculosis: 2021 update	41
COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?	41
Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial	41
Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting	41
Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study	40
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients	40
Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients	40
Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients	40
Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension	40
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society	40
The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study	39
Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study	39
A randomised trial of high-flow nasal cannula in infants with moderate bronchiolitis	39
The burden of progressive fibrotic interstitial lung disease across the UK	39
Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic?	39
The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes	38
Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort	38
Idiopathic pulmonary fibrosis: state of the art for 2023	38
Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure	38
A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension	38
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	38
A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD	38
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis	37
Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study	37
Outcome of acute hypoxaemic respiratory failure: insights from the LUNG SAFE Study	37
Understanding the pathophysiological mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards personalised treatment approaches	37
Arterial hypertension and the risk of severity and mortality of COVID-19	37
Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients	37
Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells	37
Celebrating World Tuberculosis Day at the time of COVID-19	37
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization	37
Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge	37
Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells	37
Risk stratification in pulmonary arterial hypertension using Bayesian analysis	37
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients	37
The (in)significance of TB and COVID-19 co-infection	36
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	36
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis	36
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission	36
Blood eosinophils predict inhaled fluticasone response in bronchiectasis	36
Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia	36
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection	36
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma	36
Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe	35
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)	35
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact	35
Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice	35
Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial	35